Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases
Open Access
- 1 May 2011
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (5), 2434-2437
- https://doi.org/10.1128/aac.01722-10
Abstract
The novel non-β-lactam β-lactamase inhibitor NXL104, in combination with cefepime, ceftazidime, ceftriaxone, amdinocillin, and meropenem, was tested against 190 extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates, 94 AmpC-hyperproducing E. coli isolates, and 8 AmpC/ESBL-coexpressing E. coli isolates. NXL104 restored 100% susceptibility to the partner cephalosporins for all isolates tested. Amdinocillin and meropenem MICs were modestly improved (2 to 32 times lower) by NXL104. These results suggest that NXL104 may be useful in combination with β-lactams for the treatment of infections caused by ESBL- and AmpC-producing Enterobacteriaceae .Keywords
This publication has 11 references indexed in Scilit:
- Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing EnterobacteriaceaeAntimicrobial Agents and Chemotherapy, 2011
- Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non-β-Lactam β-Lactamase InhibitorAntimicrobial Agents and Chemotherapy, 2010
- Activity of chequerboard combinations of ceftaroline and NXL104 versus -lactamase-producing EnterobacteriaceaeJournal of Antimicrobial Chemotherapy, 2010
- A Multinational Survey of Risk Factors for Infection with Extended‐Spectrum β‐Lactamase–Producing Enterobacteriaceae in Nonhospitalized PatientsClinical Infectious Diseases, 2009
- Beta-lactams and Beta-lactamase-inhibitors in current- or potential-clinical practice: A comprehensive updateCritical Reviews in Microbiology, 2009
- NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum -lactamases and carbapenemasesJournal of Antimicrobial Chemotherapy, 2008
- Comparison of Antimicrobial Resistance Profiles among Extended-Spectrum-β-Lactamase-Producing and Acquired AmpC β-Lactamase-Producing Escherichia coli Isolates from Canadian Intensive Care UnitsAntimicrobial Agents and Chemotherapy, 2008
- Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concernThe Lancet Infectious Diseases, 2008
- ampCgene expression in promoter mutants of cefoxitin-resistantEscherichia coliclinical isolatesFEMS Microbiology Letters, 2007
- Activity of mecillinam against ESBL producers in vitroJournal of Antimicrobial Chemotherapy, 2005